New Malaria Treatment Approved for Babies, Poised for Rollout in Africa

New Malaria Treatment Approved for Babies, Poised for Rollout in Africa
……………….

A newly approved malaria treatment designed specifically for babies and very young children is expected to be introduced in African countries within weeks, the BBC reported. Until now, no malaria drugs were officially approved for infants weighing less than 4.5 kg (about 10 lbs), who were treated with formulations intended for older children—posing risks of overdose.

Malaria remains a leading cause of death worldwide, with nearly 597,000 fatalities reported in 2023, the majority occurring in Africa. Children under five account for about three-quarters of these deaths. The new drug, developed by Novartis in partnership with the Medicines for Malaria Venture (MMV), addresses this “treatment gap” by providing a clinically proven, age-appropriate option for newborns and small children.

Eight African countries participated in clinical trials and are expected to be among the first to receive the treatment. Experts hail this development as a significant advance in reducing malaria mortality among the most vulnerable. MMV’s CEO Martin Fitchet called it a crucial addition to the fight against malaria, while public health specialists emphasize its potential to improve equitable access to life-saving care.